Major warfarin-related bleeding occurs more frequently in African Americans than in other populations. Identification of potential genetic factors related to this adverse event may help identify at-risk patients.
W arfarin is an effective prophylactic therapy against thromboembolic complications of vascular diseases. 1 However, balancing the benefit of anticoagulation therapy with warfarin against the inherent risk of bleeding from the drug is challenging. The risk of major bleeding from warfarin increases by 0.3% to 0.5% per year, and the risk of intracranial hemorrhage by 0.2% per year. 2 However, these values are based on studies conducted among predominantly white patients and do not account for differences in responsiveness to warfarin across ethnic groups. 3 Patients of African descent have a significantly higher rate of thromboembolic diseases like venous thromboembolism and stroke 4, 5 and a higher risk of major bleeding from warfarin than do white patients. 6 Although single-nucleotide polymorphisms (SNPs) associated with bleeding have been identified in populations of European ancestry, [7] [8] [9] [10] [11] the genetic basis for hemorrhagic complications in patients of African descent has not been well studied. Identifying these variants may help physicians make safer choices in anticoagulation therapy for this understudied patient population. The objective of this study was to identify genetic factors associated with warfarin-related bleeding among patients of African descent with an international normalized ratio (INR) of less than 4, a range in which most physicians do not consider warfarin reversal.
Methods

Participants
All participants provided written informed consent as part of the University of Chicago and the University of Illinois, Chicago institutional review board-approved protocols. All study participants were self-reported African Americans based on an open-ended question and were 18 years or older currently taking warfarin. The discovery cohort was a subset of the International Warfarin Pharmacogenetics Consortium African American genome-wide association study (GWAS) cohort 12 recruited at the University of Chicago (2009) (2010) (2011) and the University of Illinois at Chicago (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) . The replication cohort was obtained through an algorithm-driven query of the University of Chicago's Clinical Research Data Warehouse and its DNA biobank, which identified patients who routinely received care at the University of Chicago Hospitals, identified as African American, were taking warfarin, and had International Classification of Diseases, Ninth Revision (ICD-9) codes to identify whether they had had a suspected bleeding event.
All patients identified via the query (2015-2016) were then classified as cases or controls by further manual curation to validate whether bleeding occurred while they were taking warfarin at the prespecified INR threshold or whether the patient continued taking warfarin for at least 1 year with no event (eMethods in the Supplement).
Determination of Bleeding Phenotype in the Discovery and Replication Cohort
The goal of this study was to identify genetic variation associated with bleeding risk; hence, a phenotype that may have less influence from environmental causes of warfarin-related bleeding was chosen. At INR thresholds of more than 4, nongenomic factors (eg, drug-drug interactions, organ dysfunction, unintentional overdose) may have a greater association with bleeding risk than genomic factors. Thus, cases were limited to those who bled at INRs of less than 4 to provide a potential enrichment for people with a genetic predisposition to bleed. Additionally, the bleeding definition outlined below mirrors the adverse event definition in several warfarin pharmacogenomic clinical trials that report INRs of more than 4 as an adverse drug reaction. Patients with major bleeding occurring at an INR of less than 4 were considered as cases, whereas the controls were patients taking warfarin with no documented bleeding events for at least 1 year. If patients died from a fatal warfarin-related bleed within 1 year of warfarin initiation, they were retained as cases in the analysis. Major bleeding was defined as bleeding requiring hospitalization, causing a decrease in hemoglobin level of more than 2 g/dL, or requiring blood transfusion. 13 Therefore, any symptom of warfarin-associated bleeding requiring hospitalization, in any area or organ (unlike the International Society on Thrombosis and Haemostasis definition 14 ), was considered as a major bleed, to provide broader clinical applicability.
Genotyping
The discovery cohort was genotyped with the Illumina 610 Quad BeadChip (Illumina) at the RIKEN Center for Genomic Medicine, Yokohama, Japan. 12 Quality control measures such as principal component analysis for potential population stratification, thresholds for SNP and sample call rates, minor allele frequency thresholds, identity by descent exclusion to ensure only unrelated individuals were retained in the analysis and Hardy-Weinberg equilibrium were used. This was followed by postimputation info-metric thresholds, used to remove poorly imputed SNPs with low imputation certainty (detailed in eMethods). A total of 8 152 232 SNPs passed quality control filters and were used for analysis. 
Bleeding Risk Prediction
To determine if the addition of an associated SNP (rs78132896) from the identified haplotype was associated with changes in bleeding risk prediction over known clinical factors, the replication cohort was scored based on the HAS-BLED (hypertension, abnormal renal and liver function, stroke, bleeding, labile INR, elderly, and drugs or alcohol) bleeding risk prediction scheme. 13 A calculated HAS-BLED score ranges from 0 through 9, based on 9 parameters. This score assigns 1 point for each of the following risk factors: uncontrolled hypertension (>160 mm Hg systolic), abnormal renal function (dialysis, transplant, creatinine >200 mg/dL [to convert creatinine from μmol/L to mg/dL, divide by 88.4]), liver dysfunction (cirrhosis or bilirubin >2 × normal or aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase >3 × normal), stroke, prior major bleeding, older age (>65 years), medication usage predisposing to bleeding (antiplatelet agents, nonsteroidal anti-inflammatory drugs), and alcohol use (≥8 drinks/week). A high score (≥3) is indicative of increased risk of major bleeding. The discovery cohort could not be scored because sufficient clinical details at warfarin initiation were not available. Because the aim of this analysis was to evaluate the predictive accuracy of the HAS-BLED scoring system in determining bleeding risk prior to anticoagulation therapy, labile INR was scored at 0, as done previously in studies predicting bleeding risk with anticoagulant initiation.
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Statistical Analysis
To identify SNPs associated with warfarin-related bleeding, a case-control GWAS was conducted in the discovery cohort and significant SNPs with the lowest P values were studied in the replication cohort. Summary statistics from the discovery and replication cohorts were analyzed in a fixed-effect metaanalysis using METAL version 2011, 19 with the assumption that the genetic effect size would be the same across the 2 cohorts of patients of African descent with the same phenotypic outcome. A 2-sided P value of 1.62 × 10 −8 was considered the significance threshold for the discovery cohort 20 and meta-analysis. In the replication cohort, a 2-sided P value <.05 was considered significant. Association analysis was conducted by logistic regression using an additive model. Heterogeneity of the associations across the 2 cohorts was assessed by the Cochran Q statistic. Principal component 1( P = .016) and principal component 2 (P = .015), which reflected the genetic variation due to ancestry, showed an association with the bleeding phenotype and were thus included as covariates in the genetic analysis. Genetic analysis was conducted using SNPTEST version 2.5.2 for the discovery cohort and PLINK version 1.9 for the replication cohort. The frequency of the identified SNPs was compared among populations using data obtained from the 1000 Genomes project. Previously identified SNPs associated with bleeding disorders were tested for association with warfarinrelated bleeding in the discovery cohort. The gene-region plot of the top SNP associations was generated with LocusZoom version 0. 
Results
The discovery cohort comprised 31 cases with major bleeding occurring at an INR of less than 4, and 184 controls with no documented history of any warfarin-related bleeding, whereas the replication cohort consisted of 40 cases and 161 controls. However, 13 controls from the replication cohort were removed from the cohort because no genotypes were created for these samples due to failure of the assay. In the discovery cohort, the mean (SD) age was 60. . Among those with major bleeding events, 10 patients (32%) from the discovery cohort and 14 patients (35%) from the replication cohort had more than 1 major bleeding event. Gastrointestinal bleeding was the most common bleeding site in both the discovery (62%) and replication (55%) cohorts (eTable 1 in the Supplement). Abnormal renal function was significantly associated with bleeding in both the discovery (P < .001) and replication (P = .006) cohorts; therefore, all subsequent analyses were adjusted for abnormal renal function defined as dialysis, transplant, or creatinine concentrations of more than 2.6 mg/dL.
Genetic Variants and Warfarin-Related Bleeding Outcome
In the discovery cohort, 4 SNPs in linkage disequilibrium on chromosome 6 (rs115112393, rs16871327, rs78132896, and rs114504854) were associated with warfarin-related bleeding but did not reach genome-wide significance (Figure, A) . Because the allele of 1 polymorphism in a haplotype can predict the allele of adjacent nongenotyped polymorphisms, the replication cohort was genotyped for only the rs78132896 SNP, which occurred in 11 cases (35.5%) and 9 controls (4.9%) in the discovery cohort (odds ratio ), with no significant heterogeneity between cohorts detected (Cochran Q statistic P = .44). For the replication cohort, the association of the rs78132896 SNP with bleeding risk was analyzed after adjusting for the HAS-BLED score (OR, 9.38; 95% CI, 3.4-26.1; P =1.81×10 −5 ). The associated haplotype is found only in people of African ancestry (eTable 4 in the Supplement). No significant associations were observed between warfarin-related bleeding events and CYP2C9*2 (rs1799853 dbSNP; P = .40), CYP2C9*3 (rs1057910 dbSNP; P = .47), CYP2C9*5 (rs28371686 dbSNP; P = .47), CYP2C9*8 (rs7900194 dbSNP; P = .69), CYP2C9*11 (rs28371685 dbSNP; P = .12), or presence of any CYP2C9* variants (P = .50) in the replication cohort. The previously identified rs12777823 (dbSNP), 12 associated with warfarin dosing among patients of African descent, showed no association with bleeding in the discovery cohort (P = .44). Previously identified SNPs associated with bleeding disorders like polycythemia vera, 10 Von Willebrand disease, 8, 11 and Bernard-Soulier syndrome 9 did not show any significant association with bleeding in the discovery cohort (eTable 5 in the Supplement).
Functional In Vitro Assay of the Variants
The rs78132896 SNP is a promoter regulatory-region variant, upstream of the EPHA7 gene (Figure, B ). Both the rs78132896 and rs16871327 SNPs were prioritized by their highest GWAVA scores (eTable 2 in the Supplement) to construct a 6-kb haplotype vector. Luciferase reporter assays showed that the rs16871327 and rs78132896 risk alleles together increased EPHA7 gene transcription (measured as normalized luciferase activity) by a mean (SD) of 14.95 (1.7) compared with a mean 9.56 (0.84) of wild-type alleles (difference, 5.39; 95% CI, 4.1-6.6, P < .001). 
Bleeding Risk Prediction
The association between individual components of the HAS-BLED scheme and bleeding risk in the replication cohort is shown in Table 1 . The mean (SD) HAS-BLED score was 3.53 (1.26) in cases and 2.64 (1.53) in controls (P = .001). Among all the HAS-BLED covariates, only uncontrolled hypertension (P = .001), abnormal renal function (P = .006), and prior major bleeding (P = .002) were associated with major bleeding. A HAS-BLED score of 3 or higher was associated with increased risk of major bleeding (OR, 3.01; 95% CI, 1.34-6.76; P = .008). A HAS-BLED classification with a threshold of 3 (eTable 3 in the Supplement) had a sensitivity A, Single-nucleotide polymorphisms (SNPs) are plotted on the x-axis according to their positions on each chromosome against association with warfarin-associated bleeding on the y-axis (−log 10 P value). The red line shows genome-wide significant threshold of P =1.62x10 −8 . Green points toward the top of graph indicate the near-significant association found in chromosome 6. B, The colors of the circles denote linkage disequilibrium (r2) between rs78132896 (purple diamond) and nearby SNPs (based on pairwise r 2 values from the 1000 Genomes Project African population). The 3 near-significant SNPs in high linkage disequilibrium with rs78132896 are shown. The blue line and right y-axis show the estimated recombination rate (obtained from HapMap). The x-axis represents the genomic position in chromosome 6 and the left y-axis represents the -log 10 P of association with warfarin-related bleeding in the discovery cohort (n = 215). Genes at this locus are indicated in the lower panel of the plot. Chromosomal positions are based on hg19 genome build.
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Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent of 77.5% (95% CI, 69%-89%) and specificity of 46.6% (95% CI, 38%-0.55%). The rs78132896 SNP (as a tag for the entire haplotype), had a C statistic of 0.65 (95% CI, 0.58-0.73) (eFigure 5 in the Supplement). Inclusion of the rs78132896 SNP to the HAS-BLED scheme (with a threshold of 3) increased the C statistic significantly: for major bleeding, the HAS-BLED plus the SNP C statistic was 0.78 (95% CI, 0.70-0.85) and the HAS-BLED alone C statistic was 0.67 (95% CI, 0.59-0.74; C statistic difference, 0.11; 95% CI, 0.10-0.12; P = .003). Reclassification analyses showed the inclusion of the rs78132896 SNP correctly reclassified 12.5% of major bleeding events, but incorrectly reclassified 0.7% of no bleeding events, leading to an net reclassification improvement of 11.8% (P = .02), thereby increasing sensitivity to 90% (95% CI, 75%-97%) and decreasing specificity to 45.9% (95% CI, 38%-54%). The integrated discrimination index (IDI) between HAS-BLED score alone vs HAS-BLED score plus SNP was also statistically significant (IDI, 13.6%; P = .<001) (eFigure 4 in the Supplement). Because the gastrointestinal tract was the most common site of bleeding, the predictive performance of the HAS-BLED scheme was also tested for gastrointestinal bleeding in the replication cohort (eFigure 3 and eFigure 4 in the Supplement).
Discussion
This study identified a novel association of a haplotype in patients of African descent with significantly increased risk of major bleeding while taking warfarin. The associated SNPs are relatively common in among persons of African descent, as evident by the minor allele frequency of 7% in persons of African descent from the 1000 Genomes Project. 22 The haplotype is found exclusively in populations with African ancestry and therefore may represent a populationspecific genetic risk factor that exposes African Americans to a higher risk of bleeding during warfarin therapy.
Single-nucleotide polymorphism rs78132896 is located 791 bp upstream of the ephrin receptor 7 (EPHA7) within the promoter region. The EPHA7 gene is expressed in peripheral lymphocytes and vascular endothelial cells, with increased expression during inflammation. 23 (pairwise-linkage disequilibrium rs78132896 r 2 = 1) SNP is located in a CTCF transcriptional binding site. Data from the Genotype-Tissue Expression (GTEx) project was accessed to determine the potential effect of the SNPs on EPHA7 expression. However, these significant SNPs were found in less than 1% of the GTEx cohort; hence, this cohort is underpowered to find an association with gene expression. The GTEx project may not be an appropriate data set to uncover the gene expression effects of this particular finding, given the low number of African Americans with both genotype and gene expression data and the rarity of the SNPs.
A luciferase assay showed increased activity of the haplotype construct compared with the wild-type in HUVEC, 
Limitations
This study has several limitations. First, the small sample size did not allow for identification of a genome-wide significant signal in the discovery cohort. However, the 4 SNPs in linkage disequilibrium did achieve the prespecified genomewide significance threshold on meta-analysis of the combined cohorts. Second, the discovery cohort could not be scored for the HAS-BLED schema due to the lack of sufficient clinical details, and therefore improvement in bleeding risk prediction by the addition of the associated SNP to HAS-BLED schema in the replication cohort should be considered as a preliminary finding. Third, both the study cohorts were recruited at the same clinical location, and it is possible that unmeasured confounding might have influenced the results of this study. Although the medical record number of the patients recruited at the University of Chicago for the discovery and replication cohorts were matched to prevent patient overlap, patient relatedness between the 2 cohorts could not be tested by identity by descent, due to lack of genome-wide data for the replication cohort. Fourth, the C statistic CIs of the models (HAS-BLED score plus SNP vs HAS-BLED score alone) overlap. However, the CIs may overlap substantially and yet yield a statistically significant result. 34 Fifth, 13 controls from the replication cohort were not able to be genotyped. Given that the individuals removed were similar in both demographics and clinical attributes to the remaining controls, the removal of these individuals should have had little effect on the results.
Conclusions
In this preliminary study involving patients of African descent taking warfarin, 4 single-nucleotide polymorphisms in linkage disequilibrium on chromosome 6 were associated with an increased risk of major bleeding at INR of less than 4. Validation of these findings in an independent prospective cohort is required. 
SUPPLEMENTARY METHODS
Determination of bleeding phenotype in the discovery and replication cohort
The goal of this study was to identify genetic variation associated with bleeding risk; hence a phenotype that may have less influence from environmental causes of warfarin-related bleeding was chosen. At INRs of greater than 4, it is reasonable to assume that non-genomic factors (e.g. drug-drug interactions, organ dysfunction, accidental overdose) may have a greater impact on bleeding risk than genomic factors. Thus, the cases were limited to those that bled at with site of bleeding (which was confirmed via manual review) and excluded bleeding related to major trauma. After identification of a potential cohort, warfarin associated bleeding events were confirmed by manual chart review. In both cohorts, patients on warfarin with major bleeds occurring at an INR<4 were considered as cases while controls were patients with no documented bleeds while on warfarin therapy. Major bleeding was defined as bleeding requiring hospitalization and/or causing a decrease in hemoglobin level of >2 g/dL and/or requiring blood transfusion. Sixteen subjects from the discovery cohort and 12 subjects from the replication cohort were excluded for bleeds that occurred at INRs > 4. Electronic medical records were reviewed retrospectively from 2014 to 2016 to obtain clinical variables and bleeding events data. If determined to have a bleed while on warfarin, all relevant clinical data at the time of the bleeding event were also collected. Since a subset of the discovery cohort and the complete replication cohort were recruited at University of Chicago, the medical record numbers of the patients were matched to prevent any sample overlap. All participants had at least 1 year of clinical data available from the warfarin initiation date. If patients died from a fatal warfarin-related bleed within one year of warfarin initiation, they were retained as cases in the analysis.
INR at the time of bleed, data on potential bleeding risk factors and warfarin maintenance dose, defined as the same dose for at least three consecutive clinic visits that produced INRs within the therapeutic range, were collected. Patients with active malignancy, bleeding due to major trauma, or an INR≥4 at the time of bleed were excluded.
Quality control and SNP imputation
SNPs were excluded based on genotyping rate <95%, minor allele frequency <5%, 5 and failed Hardy-Weinberg equilibrium tests p <0.00001. SNPs were also excluded if they were: A/T or C/G SNPs to eliminate flip-strand issues, SNPs on the X and Y chromosomes or mitochondrial SNPs. Genome-wide genotype data was used to validate gender and identity-by-descent. No sample had a call rate of <95%, missingness >0.05, gender misspecification, or IBD >0.125. Additionally, principal components 1 and 2 were used to confirm ancestry of all individuals with any outliers removed. Genotypes were phased using SHAPEIT and imputed with IMPUTE2 using reference files from the 1,000
Genomes haplotypes --Phase I integrated variant set release (v3) in NCBI build 37 (hg19) coordinates. 
